Mancia 28/7/08 12:57 pm Page 78
Hypertension
evidence that inflammation is a component of atherosclerosis and that thus become a future goal, in light also of the importance given by the
inflammatory markers may therefore be important predictors of the ESH/ESC guidelines
2
to the effect of treatment on precursors of events
outcome of patients.
20
Improvement of these markers by treatment may such as risk factors, organ damage and new-onset high-risk conditions. ■
1. Turnell F, Blood Pressure Lowering Treatment Trialists’ 8. Kuschnir E, Bendersky M, Resk J, et al., Effects of the 14. Weber MA, Julius S, Kjeldsen SE, et al., Blood pressure
Collaboration. Effects of different blood-pressure-lowering combination of low-dose nifedipine GITS 20 mg and losartan dependent and independent effects of antihypertensive
regimens on major cardiovascular events: results of 50 mg in patients with mild to moderate hypertension, treatment on clinical events in the VALUE Trial, Lancet,
prospectively designed overviews of randomised trials, Lancet, J Cardiovasc Pharmacol, 2004;43:300–305. 2004;363:2049–51.
2003;362:1527–35. 9. Lacourcière Y, Gil-Extremera B, Mueller O, et al., Efficacy and 15. Volpe M, Rosei EA, Ambrosioni E, et al., Reduction in
2. Mancia G, De Backer G, Dominiczak A, et al., 2007 Guidelines tolerability of fixed-dose combinations of telmisartan plus estimated stroke risk associated with practice-based stroke-risk
for the Management of Arterial Hypertension: The Task Force HCTZ compared with losartan plus HCTZ in patients with assessment and awareness in a large, representative
for the Management of Arterial Hypertension of the European essential hypertension, Int J Clin Pract, 2003;57:273–9. population of hypertensive patients: results from the ForLife
Society of Hypertension (ESH) and of the European Society of 10. Sega R, Facchetti R, Bombelli M, et al., Prognostic value of study in Italy,
Cardiology (ESC), J Hypertens, 2007;25:1105–87. ambulatory and home blood pressures compared with office J Hypertens, 2007;25:2390–97.
3. Law MR, Wald NJ, Morris JK, Jordan RE, Value of low dose blood pressure in the general population: follow-up results 16. Kannel WB, Blood pressure as a cardiovascular risk factor:
combination treatment with blood pressure lowering drugs: from PAMELA Study, Circulation, 2005;111(14):1777–83. prevention and treatment, JAMA, 1996;275:1571–6.
analysis of 354 randomised trials, BMJ, 2003;326:1427. 11. Sega R, Corrao G, Bombelli M, et al., Blood pressure variability 17. Mancia G, Parati G, Guiding antihypertensive treatment
4. Bakris G, Molitch M, Hewkin A, et al.; STAR Investigators, and organ damage in a general population: results from the decisions using ambulatory blood pressure monitoring,
Differences in glucose tolerance between fixed-dose PAMELA study (Pressioni Arteriose Monitorate E Loro Curr Hypertens Rep, 2006;8:330–37.
antihypertensive drug combinations in people with metabolic Associazioni), Hypertension, 2002;39:710–14. 18. Ibsen H, Olsen MH, Wachtell K, et al., Reduction in
syndrome, Diabetes Care, 2006;29:2592–7. 12. Kario K, Yasui N, Yokoi H, Ambulatory blood pressure albuminuria translates to reduction in cardiovascular events in
5. Mancia G, Grassi G, Zanchetti A, New onset diabetes and monitoring for cardiovascular medicine, IEEE Eng Med Biol Mag, hypertensive patients: losartan intervention for endpoint
antihypertensive drugs, J Hypertens, 2006;24:3–10. 2003;22:81–8. reduction in hypertension study, Hypertension,
6. Jamerson K, Bakris GL, Dahlöf B, et al.; ACCOMPLISH 13. Chobanian AV, Bakris GL, Black HR, et al.; National Heart, 2005;45:198–202.
Investigators, Exceptional early blood pressure control rates: Lung, and Blood Institute Joint National Committee on 19. de Zeeuw D, Remuzzi G, Parving HH, et al., Albuminuria, a
the ACCOMPLISH trial, Blood Press, 2007;16:80–86. Prevention, Detection, Evaluation, and Treatment of High therapeutic target for cardiovascular protection in type 2
7. Allemann Y, Farile B, Lambert M, et al., Efficacy of the Blood Pressure; National High Blood Pressure Education diabetic patients with nephropathy, Circulation,
combination of amlodipine and valsartan in patients with Program Coordinating Committee, The Seventh Report of the 2004;110:921–7.
hypertension uncontrolled with previous monotherapy: the Joint National Committee on Prevention, Detection, Evaluation, 20. Savoia C, Schiffrin EL, Vascular inflammation in hypertension
Exforge in Failure after Single Therapy (EX-FAST) study, J Clin and Treatment of High Blood Pressure: the JNC 7 report, and diabetes: molecular mechanisms and therapeutic
Hypertens (Greenwich), 2008;10(3):185–94. JAMA, 2003; 289(19):2560–72. interventions, Clin Sci (Lond), 2007;112:375–84.
Events for the Diary
26–29 July 18–21 September 11–15 October
14th World Congress on Heart Disease American Association of Annual Congress of the European
International Academy of Cardiology Cardiovascular and Pulmonary Association of Nuclear Medicine
Annual Scientific Sessions Rehabilitation Annual Meeting Munich, Germany
Toronto, Canada Indianapolis, IN, US
www.eanm.org
www.cardiologyonline.com
www.aacvpr.org
12–17 October
30 August – 3 September 27–30 September Transcatheter Cardiovascular
European Society of Cardiology European Association Therapeutics
Annual Congress of Cardiothoracic Washington, DC, US
Munich, Germany Anaesthesiologists
www.tctconference.com
www.escardio.org Rome, Italy
www.eacta.org 30 October – 2 November
10–14 September Controversies to Consensus
American Society of 11–14 October in Diabetes, Obesity
Nuclear Cardiology Acute Cardiac Care 2008 and Hypertension
Boston, MA, US Versailles, France Barcelona, Spain
www.asnc.org www.escardio.org
www.codhy.com/2008
13–17 September 11–14 October 10–13 December
22nd European Association of North American Society for EUROECHO 2008 –
Cardiothoracic Surgery Cardiovascular Imaging Annual Meeting of the European
Annual Meeting 36th Annual Meeting Association of Echocardiography
Lisbon, Portugal Scottsdale, AZ Lyon, France
www.eacts.org www.nasci.org
www.escardio.org
78 EUROPEAN CARDIOLOGY
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116